DYSF and autosomal recessive limb-girdle muscular dystrophy type 2D: Turan et al. [92] employed the CRISPR/Cas9 gene editing system to correct DYSFERLIN and α-sarcoglycan mutations in LGMD2B and LGMD2D patient-derived iPSCs, respectively.